Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1 for drug discovery and mechanism of action (MOA) research

Pre-Made Rozibafusp Alfa Biosimilar, Fusion Protein targeting ICOS fused with human TNFSF13B (tumor necrosis factor (TNF) superfamily member 13B, BAFF, THANK, TALL1, TALL-1, BLYS, BLyS, B cell activating factor, B lymphocyte activator, CD257): Recombinant therapeutic protein targeting AILIM/CD278/CVID1 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with dysregulated T cell and B cell responses. Rozibafusp alfa is a bispecific molecule targeting T cell and B cell activity through inhibition of the inducible costimulator ligand (ICOSL) and the B cell activating factor (BAFF). Targeting both ICOSL and BAFF will be more effective than single target inhibition in SLE and other autoimmune diseases.